ANDA 214308, held by Regcon Holdings. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 214308 (Succinylcholine Chloride), held by Regcon Holdings, was first approved by FDA on May 22, 2020, with 2 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 22, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Oct 29, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 5, 2020 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| May 22, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters